Aldosterone ( DrugBank: Aldosterone )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
222	Primary nephrotic syndrome	2

222. Primary nephrotic syndrome

---

Clinical trials : 310 /  Drugs : 295 - (DrugBank : 117) / Drug target genes : 63 - Drug target pathways : 194

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01508468 (ClinicalTrials.gov)	January 17, 2012	9/12/2011	Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy	Prospective Randomized Multicentric Open Label Study to Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy (IMN)	Idiopathic Membranous Nephropathy	Drug: symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin);Drug: experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)	Assistance Publique - Hôpitaux de Paris	NULL	Completed	18 Years	N/A	All	80	Phase 3	France
2	NCT01129557 (ClinicalTrials.gov)	September 2009	21/5/2010	Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease	Aldosterone Breakthrough During Diovan (Valsartan), Tekturna (Aliskiren), and Combination (Valsartan+Aliskiren) Anti-hypertensive Therapy in Patients With Proteinuric Kidney Disease	Proteinuric Kidney Disease;Diabetic Nephropathy;Hypertensive Nephrosclerosis;IgA Nephropathy;Focal Segmental Glomerulosclerosis;Glomerulopathy (Obesity-associated);Glomerulonephritis, Membranous	Drug: Aliskiren;Drug: Valsartan	Columbia University	Novartis Pharmaceuticals	Terminated	18 Years	N/A	All	46	Phase 4	United States